<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04978428</url>
  </required_header>
  <id_info>
    <org_study_id>IRB21-1147</org_study_id>
    <nct_id>NCT04978428</nct_id>
  </id_info>
  <brief_title>Epidiolex in Obsessive Compulsive Disorder</brief_title>
  <official_title>An Open-Label Trial of Epidiolex in the Treatment of Obsessive Compulsive Disorder: Proof of Concept Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the proposed study is to evaluate the safe and efficacy of Epidiolex&#xD;
      (cannabidiol) in adults with obsessive compulsive disorder (OCD). Subjects will be treated in&#xD;
      an open-label fashion with Epidiolex for two weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the proposed study is to evaluate the safety and efficacy of&#xD;
      Epidiolex (cannabidiol) in adults with obsessive compulsive disorder (OCD). Fifteen subjects&#xD;
      with OCD will be treated in an open-label fashion with Epidiolex (2.5 mg/kg twice daily for&#xD;
      one week followed by 5mg/kg twice daily) for two total weeks of active treatment. The&#xD;
      hypothesis to be tested is that Epidiolex will result in reduction in symptoms of OCD&#xD;
      (improvement in symptoms will be indicated by lower scores on established outcome measures of&#xD;
      OCD symptoms that have been used in prior studies).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Open-Label treatment study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Brown Obsessive Compulsive Scale (YBOCS)</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>The primary outcome measure will be the change from baseline using the Yale Brown Obsessive Compulsive Scale (YBOCS). The YBOCS is a 10-item scale that assesses OCD symptoms during the last seven days. The first five items comprise the urge/thought subscale and items 6-10 comprise the behavior subscale.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions- Improvement Scale (CGI-I)</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>The entire study for the subject will last 8 weeks. Every week the subject will complete the CGI. The change in scores from baseline to after 8 weeks will be assessed. The scale itself assesses overall disorder severity on a scale from 1 to 7 with 1 being &quot;not at all&quot; and 7 being &quot;among the most severe cases&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale (HAM-D)</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>A clinician-administered assessment of depression that will be assessed at all study visits. Higher total scores indicate higher levels of depression, while a score of 0 would indicate no depressive symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hamilton Anxiety Rating Scale (HAM-A)</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>A clinician-administered assessment of anxiety that will be assessed at all study visits. Changes in scores from baseline to final visit will be assessed. Higher scores indicate higher levels of anxiety, with 0 being no symptoms of anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sheehan Disability Scale (SDS)</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>Subjects will complete the SDS at all visits. The change in scores from baseline to study completion will be assessed. The scale itself assesses the level of disability from target disorder with higher scores indicating a more debilitating disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Inventory (QOLI)</measure>
    <time_frame>Baseline to Week 2</time_frame>
    <description>A self-report assessment of patient perceived quality of life that will be assessed at baseline and week 8. Higher scores indicate a higher quality of life, whereas lower scores indicate a lower quality of life.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Obsessive-Compulsive Disorder</condition>
  <arm_group>
    <arm_group_label>Epidiolex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epidiolex (2.5 mg/kg twice daily for one week) followed by Epidiolex (5mg/kg twice daily for two weeks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cannabidiol</intervention_name>
    <description>Epidiolex oral solution (2.5 mg/kg and 5 mg/kg)</description>
    <arm_group_label>Epidiolex</arm_group_label>
    <other_name>Epidiolex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women age 18-65&#xD;
&#xD;
          -  Primary diagnosis of OCD&#xD;
&#xD;
          -  YBOCS score of at least 18 at baseline&#xD;
&#xD;
          -  Ability to understand and sign the consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unstable medical illness based on history or clinically significant abnormalities on&#xD;
             baseline physical examination or labs&#xD;
&#xD;
          -  Current pregnancy or lactation, or inadequate contraception in women of childbearing&#xD;
             potential&#xD;
&#xD;
          -  Subjects considered an immediate suicide risk based on the Columbia Suicide Severity&#xD;
             Rating Scale (C-SSRS)&#xD;
&#xD;
          -  Past 12-month DSM-5 psychiatric disorder other than OCD&#xD;
&#xD;
          -  Illegal substance use based on urine toxicology screening&#xD;
&#xD;
          -  Initiation of psychological interventions within 3 months of screening&#xD;
&#xD;
          -  Use of any other psychotropic medication&#xD;
&#xD;
          -  Previous treatment with epidiolex&#xD;
&#xD;
          -  Cognitive impairment that interferes with the capacity to understand and&#xD;
             self-administer medication or provide written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jon E Grant, MD, JD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eve K Chesivoir, BA</last_name>
    <phone>7737029066</phone>
    <email>chesivoir@yoda.bsd.uchicago.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Valle, BA</last_name>
    <phone>(773) 834-3778</phone>
    <email>svalle@yoda.bsd.uchicago.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Eve K Chesivoir, BA</last_name>
      <phone>773-702-9066</phone>
      <email>chesivoir@yoda.bsd.uchicago.edu</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Valle, BA</last_name>
      <phone>(773) 834-3778</phone>
      <email>svalle@yoda.bsd.uchicago.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jon E Grant, MD, JD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Blanco C, Olfson M, Stein DJ, Simpson HB, Gameroff MJ, Narrow WH. Treatment of obsessive-compulsive disorder by U.S. psychiatrists. J Clin Psychiatry. 2006 Jun;67(6):946-51.</citation>
    <PMID>16848654</PMID>
  </reference>
  <reference>
    <citation>Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry. 2006 Jul;11(7):622-32. Epub 2006 Apr 4. Review. Erratum in: Mol Psychiatry. 2006 Aug;11(8):795.</citation>
    <PMID>16585942</PMID>
  </reference>
  <reference>
    <citation>Frisch MB, Cornell J, Villaneuva M (1993). Clinical validation of the Quality of Life Inventory: a measure of life satisfaction for use in treatment planning and outcome assessment. Psychol Assess. 4:92-101.</citation>
  </reference>
  <reference>
    <citation>Grant JE. Clinical practice: Obsessive-compulsive disorder. N Engl J Med. 2014 Aug 14;371(7):646-53. doi: 10.1056/NEJMcp1402176. Review.</citation>
    <PMID>25119610</PMID>
  </reference>
  <reference>
    <citation>HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62.</citation>
    <PMID>14399272</PMID>
  </reference>
  <reference>
    <citation>HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5.</citation>
    <PMID>13638508</PMID>
  </reference>
  <reference>
    <citation>Ravizza L, Barzega G, Bellino S, Bogetto F, Maina G. Predictors of drug treatment response in obsessive-compulsive disorder. J Clin Psychiatry. 1995 Aug;56(8):368-73.</citation>
    <PMID>7635854</PMID>
  </reference>
  <reference>
    <citation>Sheehan DV (1983). The Anxiety Disease. New York: Scribner's.</citation>
  </reference>
  <reference>
    <citation>Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. Review.</citation>
    <PMID>9881538</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 20, 2021</study_first_submitted>
  <study_first_submitted_qc>July 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obsessive Compulsive Disorder</keyword>
  <keyword>CBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Compulsive Personality Disorder</mesh_term>
    <mesh_term>Obsessive-Compulsive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cannabidiol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

